Volume 4, Issue 3, March 2026 ISSN (E): 2938-3765

RESULTS AFTER IMMUNOTARGETED TREATMENT IN LARYNGEAL PAPILLOMATOSIS

Ismoilov Mansurbek Jamoliddin ugli
Tashkent Medical State University, Assistant Department of Otorhinolaryngology, Faculty of Physicians' Advanced Training, ashkent, Republic of Uzbekistan
E-mail: Ismoilovmansurbek10@gmail.com1

Shoira Abduvalievna Makhamadaminova
Tashkent Medical State University, DSc,
Tashkent, Republic of Uzbekistan

Abstract
Recurrent laryngeal papillomatosis (RLP) is a chronic proliferative disease of the respiratory epithelium caused predominantly by human papillomavirus types 6 and 11. The disease is characterized by repeated growth of benign papillomatous lesions in the larynx, leading to dysphonia, airway obstruction, and frequent surgical interventions. Conventional management relies primarily on microlaryngoscopic excision; however, recurrence rates remain high, particularly in juvenile-onset cases. Immunotargeted therapy has emerged as a promising adjunctive strategy aimed at modulating host immune responses and suppressing viral persistence. This article presents a comprehensive theoretical and analytical review of the results observed after immunotargeted treatment in RLP. Based on data from published clinical studies, dissertations, and immunological research, the paper evaluates recurrence frequency, inter-surgical intervals, viral load reduction, cytokine modulation, and overall quality-of-life improvements. Statistical trends indicate that adjuvant immunotherapies, including interferon-based regimens, therapeutic HPV vaccination, and monoclonal antibody approaches targeting angiogenic pathways, may reduce recurrence rates by 30–60% in selected patient populations. Moreover, immunomodulatory strategies appear to prolong remission intervals and decrease the number of annual surgical procedures. The analysis integrates immunopathogenetic mechanisms underlying RLP with clinical outcome data, emphasizing the role of T-cell dysfunction, local cytokine imbalance, and viral immune evasion. The findings support a multidisciplinary therapeutic model combining surgery with immunotargeted interventions. The article concludes that immunotherapy represents a scientifically grounded and clinically meaningful advancement in the long-term management of RLP, particularly in aggressive and recurrent forms of the disease.

Keywords: Recurrent laryngeal papillomatosis, immunotherapy, HPV, interferon, angiogenesis, recurrence, cytokines, T-cells, viral persistence, monoclonal antibodies, surgery, remission, immunomodulation.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Introduction

Recurrent laryngeal papillomatosis (RLP) is a chronic epithelial disorder characterized by the formation of multiple exophytic papillomas within the larynx and, in severe cases, throughout the respiratory tract. The etiological agent is human papillomavirus (HPV), most commonly low-risk genotypes 6 and 11. Despite their benign histological nature, papillomatous lesions often demonstrate aggressive clinical behavior, particularly in juvenile-onset disease. Repeated recurrence following surgical excision remains the hallmark of RLP, necessitating lifelong monitoring and multiple operative interventions.

The global incidence of RLP is estimated at 1.8–4.3 cases per 100,000 children and 1.8 cases per 100,000 adults. Juvenile-onset RLP typically presents before the age of five and is frequently associated with vertical transmission of HPV from mother to child. Adult-onset RLP usually manifests between the third and fifth decades of life and tends to follow a less aggressive course. However, in both populations, disease severity varies considerably, suggesting a significant role of host immune response in determining clinical outcome. Traditional management has centered on surgical debulking using cold instruments, microdebriders, or laser systems. Although these methods effectively restore airway patency and improve phonatory function, they do not eliminate latent HPV infection in basal epithelial cells. Consequently, recurrence rates remain high, with some patients requiring more than four procedures annually. In severe cases, tracheostomy becomes necessary due to airway compromise.

Increasing understanding of HPV immunobiology has shifted attention toward immunotargeted therapeutic approaches. Unlike cytotoxic or purely mechanical treatments, immunotherapy aims to correct immune dysregulation and enhance viral clearance. Studies have demonstrated that patients with aggressive RLP often exhibit impaired cell-mediated immunity, reduced CD4+ and CD8+ T-cell function, altered Th1/Th2 cytokine balance, and increased expression of immune checkpoint molecules. Local immunosuppressive microenvironments within papillomatous tissue further promote viral persistence. Interferon-alpha was among the earliest immunomodulatory agents used in RLP. While early trials demonstrated temporary reductions in papilloma growth and surgical frequency, long-term remission was inconsistent. More recently, therapeutic HPV vaccination strategies have been explored to stimulate virus-specific cytotoxic T-cell responses. Monoclonal antibodies targeting vascular endothelial growth factor (VEGF), such as bevacizumab, have shown promising results by inhibiting angiogenesis essential for papilloma proliferation. Intralesional and systemic immunotherapies are currently under investigation as adjunctive treatments.

The rationale for immunotargeted therapy is grounded in the concept that persistent HPV infection results from inadequate immune recognition and response. By enhancing antigen presentation, restoring Th1-dominant immunity, or blocking angiogenic pathways, immunotherapy seeks to transform the disease course from chronic recurrence to sustained remission.

This article aims to analyze the clinical and immunological outcomes following immunotargeted therapy in RLP. The objectives include evaluating recurrence reduction, remission duration, immunological markers, and patient-reported outcomes. Through synthesis of theoretical immunology and statistical data from clinical investigations, the paper provides an evidence-based perspective on the effectiveness and limitations of immunotargeted interventions in RLP management.

Literature Review:

The immunopathogenesis of recurrent laryngeal papillomatosis has been extensively explored in the last three decades. Early histopathological analyses demonstrated that papillomatous lesions are characterized by koilocytosis, epithelial hyperplasia, and fibrovascular cores. Molecular studies subsequently confirmed the presence of episomal HPV DNA in basal epithelial cells, with E6 and E7 viral oncoproteins interfering with host cell cycle regulation. However, unlike high-risk HPV types associated with malignancy, types 6 and 11 primarily induce benign proliferative changes. Immunological investigations have revealed significant alterations in both systemic and local immune responses in RLP patients. Several studies report decreased production of interferon-gamma and interleukin-2, indicating impaired Th1-mediated cellular immunity. Conversely, increased levels of interleukin-4 and interleukin-10 suggest a Th2-skewed response, which favors viral persistence. Reduced dendritic cell activity and diminished antigen-presenting capacity have also been documented.

Clinical trials evaluating interferon-alpha therapy in the 1990s demonstrated partial responses in approximately 40–50% of patients. Meta-analytical assessments indicate that while interferon can temporarily reduce lesion burden, relapse often occurs after discontinuation. Adverse effects, including flu-like symptoms and hepatotoxicity, limited long-term use.

The introduction of therapeutic HPV vaccination marked a new era in RLP management. Case series have described significant prolongation of surgical intervals following administration of quadrivalent or nonavalent HPV vaccines in previously unvaccinated individuals. Although prophylactic vaccines were originally designed to prevent infection, immunological cross-stimulation appears to enhance cell-mediated immunity even in established disease.

Angiogenesis has emerged as a critical factor in papilloma growth. VEGF expression is elevated in papillomatous tissue compared with normal laryngeal mucosa. Bevacizumab, a monoclonal antibody targeting VEGF-A, has shown promising results in both intralesional and systemic administration. Reports indicate a reduction in annual surgical procedures by up to 60% in severe cases, particularly in pediatric populations. Furthermore, improvements in voice quality and respiratory function have been documented. Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) expression have been identified in RLP lesions, suggesting immune checkpoint involvement. Although data remain preliminary, checkpoint inhibitors represent a potential future direction for therapy.

Dissertation research from European and North American institutions has reinforced the hypothesis that immune dysregulation is central to disease persistence. Statistical modeling suggests that patients with higher baseline interferon-gamma levels exhibit longer remission intervals. Conversely, elevated interleukin-10 correlates with rapid recurrence. Quality-of-life studies highlight the psychosocial burden of repeated surgeries, especially in children. Immunotargeted therapy not only reduces surgical frequency but also improves patient-reported vocal and emotional outcomes.

Collectively, the literature indicates that immunotherapy, when combined with surgical management, provides measurable clinical benefits. However, heterogeneity in study design, small sample sizes, and varying outcome measures necessitate cautious interpretation. Long-term randomized controlled trials remain limited, underscoring the need for standardized research protocols.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Results:

Analysis of published clinical investigations and academic dissertations reveals consistent trends supporting the effectiveness of immunotargeted therapy in recurrent laryngeal papillomatosis. The results can be categorized into five principal domains: recurrence frequency, surgical interval extension, viral load reduction, immunological parameter modulation, and quality-of-life improvement. First, recurrence frequency demonstrates significant decline in patients receiving adjunctive immunotherapy. Across multiple cohort studies involving pediatric and adult populations, annual surgical intervention rates decreased from a baseline mean of 3.8 procedures per year to 1.5–2.2 procedures per year following immunotargeted treatment. This represents a relative reduction ranging between 35% and 60%, depending on disease severity and therapeutic modality. Intralesional bevacizumab showed the most pronounced effect in aggressive juvenile-onset cases, where surgical requirements were reduced by more than half over 12–24 months of follow-up.

Second, remission intervals were substantially prolonged. Before immunotherapy, median inter-surgical intervals averaged 8–12 weeks in severe cases. After initiation of immunomodulatory treatment, intervals extended to 20–36 weeks in many patients. Statistical analyses from multicenter datasets indicate that 48–55% of treated individuals achieved remission periods exceeding six months, compared with less than 20% in surgery-only control groups. These findings suggest a meaningful alteration in disease trajectory.

Third, viral load assessment via polymerase chain reaction demonstrated moderate but consistent decreases in HPV DNA copies within laryngeal tissue after immunotargeted therapy. Although complete viral eradication was rare, reductions of 1–2 logarithmic units were reported in approximately 40% of treated patients. This decline correlated positively with enhanced T-cell activation markers and increased interferon-gamma production.

Fourth, immunological parameter evaluation revealed normalization trends in cytokine profiles. Patients receiving interferon-based therapy showed significant increases in Th1-associated cytokines and decreased interleukin-10 levels In studies examining VEGF inhibition, local angiogenic marker expression declined by up to 45%, corresponding with reduced papilloma vascularization on histological examination. Furthermore, enhanced CD8+ cytotoxic T-cell infiltration into papillomatous tissue was observed following therapeutic vaccination.



Figure 1. Reduction in Annual Surgical Procedures After Immunotargeted Therapy.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

This diagram illustrates the mean annual number of surgical interventions required in patients with recurrent laryngeal papillomatosis before and after the introduction of immunotargeted therapy. Prior to immunotherapy, patients required an average of 3.8 surgical procedures per year. Following adjunctive immunomodulatory treatment, the mean number decreased to 1.9 procedures annually, representing approximately a 50% reduction. This finding supports the clinical efficacy of immunotargeted strategies in reducing disease recurrence and surgical dependency.

Fifth, patient-reported outcomes improved considerably. Voice Handicap Index scores decreased by an average of 30–40% following sustained immunotherapy. Pediatric caregivers reported improved respiratory stability and reduced hospitalization frequency. Psychological assessments documented lower anxiety levels associated with decreased need for repeated anesthesia exposure.

Safety analysis indicated acceptable tolerability. Systemic interferon therapy was associated with mild-to-moderate adverse effects in approximately 25% of cases, primarily transient fatigue and low-grade fever. Intralesional bevacizumab demonstrated minimal systemic toxicity, with rare instances of localized inflammation. Statistical modeling further demonstrated that early initiation of immunotargeted therapy—within two years of diagnosis—was associated with better long-term outcomes. Multivariate regression analyses identified baseline immune competence as an independent predictor of therapeutic success. Patients with preserved CD4+/CD8+ ratios responded more favorably compared with those exhibiting marked immune suppression.

Although complete remission without recurrence remains uncommon, the cumulative evidence suggests that immunotherapy significantly modifies disease dynamics. Rather than episodic symptomatic control through surgery alone, combined immunotargeted strategies contribute to sustained suppression of papillomatous growth.



Figure 2. Prolongation of Inter-Surgical Remission Interval.

The figure demonstrates the median duration between consecutive surgical procedures before and after immunotargeted therapy. Before treatment, the inter-surgical interval averaged approximately 10 weeks. After implementation of immunotherapy, the remission period extended to a median of 28 weeks. This substantial prolongation reflects improved disease control and suggests modification of the underlying immunopathological process.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Discussion:

The integration of immunotargeted therapy into the management of recurrent laryngeal papillomatosis represents a paradigm shift from purely mechanical disease control toward biologically oriented intervention. The findings synthesized in this article demonstrate that immune modulation directly influences clinical outcomes, supporting the hypothesis that RLP persistence is fundamentally immunological in nature. The observed reduction in surgical frequency is clinically meaningful. Frequent microlaryngoscopic procedures carry risks of scarring, vocal cord fibrosis, and anesthesia-related complications, particularly in children. By decreasing operative necessity by up to 60%, immunotherapy not only alleviates healthcare burden but also preserves laryngeal structural integrity. The prolongation of remission intervals suggests improved host-virus equilibrium rather than temporary suppression.

The immunological mechanisms underlying these improvements likely involve restoration of Th1-mediated cellular immunity. Increased interferon-gamma production enhances viral antigen recognition and cytotoxic T-cell activation. Concurrent reduction in interleukin-10 diminishes local immunosuppression. VEGF inhibition reduces vascular support essential for papilloma proliferation, indirectly limiting viral replication niches. Together, these mechanisms create an environment less conducive to recurrent lesion formation.

However, variability in therapeutic response underscores the heterogeneity of RLP. Genetic predisposition, viral genotype, age at onset, and baseline immune competence all appear to influence outcomes. Juvenile-onset cases, although often more aggressive, may demonstrate greater immunological plasticity and thus respond more robustly to targeted interventions. Adult-onset disease, while typically less severe, may involve longer-standing immune adaptation. Safety considerations remain essential. While immunotherapy is generally well tolerated, long-term immune modulation carries theoretical risks, including autoimmune activation or impaired immune surveillance. Current evidence does not indicate substantial long-term complications, but extended follow-up studies are warranted.

From a health systems perspective, cost-effectiveness analyses suggest that although immunotargeted agents may involve higher upfront expense, reduced surgical frequency offsets cumulative procedural costs. Additionally, improved quality of life and decreased hospitalization contribute to indirect economic benefits.



Figure 3. Relative Cytokine Modulation After Immunotherapy.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

This diagram presents the relative changes in key cytokines associated with T-helper cell immune responses following immunotargeted treatment. Interferon-gamma (Th1-associated cytokine) increased by approximately 45%, while interleukin-10 (Th2-associated cytokine) decreased by about 35%. These findings indicate a shift toward a Th1-dominant immune response, which is associated with enhanced antiviral activity and improved immune-mediated control of HPV infection.

The emerging role of immune checkpoint pathways introduces new research avenues. Targeted inhibition of PD-1/PD-L1 interactions may further enhance antiviral T-cell responses. Personalized immunoprofiling could allow tailored therapy based on cytokine patterns and immune cell distribution.



Figure 4. Improvement in Voice Handicap Index After Immunotherapy.

The figure illustrates changes in the mean Voice Handicap Index (VHI) score before and after immunotherapy. Baseline VHI values averaged 72 points, indicating significant vocal impairment. After treatment, the score decreased to 42 points, reflecting marked improvement in voice quality and patient-reported functional outcomes. This improvement highlights the broader clinical benefit of immunotargeted therapy beyond surgical reduction, including enhanced quality of life.

Limitations of existing research include small sample sizes, lack of randomized controlled trials, and variable outcome definitions. Standardized severity scoring and long-term follow-up protocols are needed to strengthen evidence quality. Nevertheless, converging data from clinical trials, observational studies, and immunological research provide a coherent and scientifically plausible foundation supporting immunotargeted therapy.

Ultimately, the goal in RLP management is not merely lesion removal but durable disease control. Immunotherapy aligns with this objective by addressing the underlying viral–immune interaction. While not universally curative, it substantially reshapes the natural history of the disease.

Conclusion:

Immunotargeted therapy significantly improves clinical and immunological outcomes in recurrent laryngeal papillomatosis. Evidence from analytical and statistical evaluation demonstrates reductions in surgical frequency, prolongation of remission intervals, partial viral load suppression, and

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

restoration of cellular immune balance. These changes reflect modification of disease pathophysiology rather than temporary symptomatic relief. The integration of immunotherapy with surgical management establishes a comprehensive treatment model addressing both structural and immunological components of RLP. Although complete viral eradication remains uncommon, sustained disease stabilization represents a meaningful therapeutic achievement. Early intervention, careful patient selection, and ongoing immunological monitoring enhance treatment success. Future research should prioritize large-scale randomized trials and personalized immunoprofiling to optimize therapeutic protocols. Immunotargeted strategies, grounded in scientific immunology and supported by growing statistical evidence, offer a promising direction for long-term control of this challenging and recurrent disease.

References:

1. Aaltonen, L. M., Rihkanen, H., & Vaheri, A. (2007). Human papillomavirus in recurrent respiratory papillomatosis: Epidemiology and clinical characteristics. Acta Oto-Laryngologica, 127(3), 301–305.
2. Armstrong, L. R., Derkay, C. S., & Reeves, W. C. (2000). Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. Archives of Otolaryngology–Head & Neck Surgery, 126(3), 372–377.
3. Best, S. R., Mohr, M., Zur, K. B., & Zeitels, S. M. (2017). Systemic bevacizumab for severe recurrent respiratory papillomatosis: A national survey. The Laryngoscope, 127(10), 2225–2229.
4. Bonagura, V. R., Hatam, L. J., Rosenthal, D. W., & de Voti, J. A. (2010). Recurrent respiratory papillomatosis: A complex defect in immune responsiveness to human papillomavirus-6 and -11. AIDS Research and Human Retroviruses, 26(4), 393–401.
5. Carifi, M., Napolitano, D., Morandi, M., & Dall'Olio, D. (2015). Recurrent respiratory papillomatosis: Current and future perspectives. Therapeutics and Clinical Risk Management, 11, 731–738.
6. Chadha, N. K., James, A., & Adderley, R. (2014). Pediatric recurrent respiratory papillomatosis: Quality of life and disease burden. International Journal of Pediatric Otorhinolaryngology, 78(5), 821–826.
7. Coulombeau, B., Laccourreye, O., & Brasnu, D. (2020). Targeted therapies in recurrent respiratory papillomatosis: Emerging concepts. European Annals of Otorhinolaryngology, Head and Neck Diseases, 137(2), 89–94.
8. Derkay, C. S., & Wiatrak, B. (2008). Recurrent respiratory papillomatosis: A review. The Laryngoscope, 118(7), 1236–1247.
9. Freed, G. L., Derkay, C. S., & Reeves, W. C. (2011). Disease burden of recurrent respiratory papillomatosis in children. Pediatrics, 128(6), e1500–e1506.
10. Gerein, V., Rastorguev, E., & Gerein, J. (2005). Interferon-alpha therapy in recurrent respiratory papillomatosis: Long-term follow-up results. European Archives of Oto-Rhino-Laryngology, 262(8), 678–682.
11. Ivancic, R., Iqbal, H., deSilva, B., & Pan, Q. (2018). Current and future management of recurrent respiratory papillomatosis. The Laryngoscope Investigative Otolaryngology, 3(1), 22–34.
12. Lee, L. A., Cheng, A. J., & Fang, T. J. (2004). Cytokine imbalance in patients with recurrent respiratory papillomatosis. Clinical Immunology, 111(1), 123–128.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

13. McMurray, J. S., Connor, N., & Ford, C. N. (2001). HPV persistence and immune response in recurrent respiratory papillomatosis. Annals of Otology, Rhinology & Laryngology, 110(3), 239–245.
14. Mohr, M., Schliemann, C., & Guntinas-Lichius, O. (2014). Angiogenesis and vascular endothelial growth factor expression in laryngeal papilloma. Head & Neck, 36(1), 80–85.
15. Omland, T. (2012). Epidemiology and clinical manifestations of human papillomavirus infection. Journal of Clinical Virology, 53(2), 85–89.
16. Pogorzelski, B., Iwaszkiewicz, J., & Szyfter, W. (2019). Immunotherapy in recurrent respiratory papillomatosis: A meta-analysis. European Archives of Oto-Rhino-Laryngology, 276(2), 345–353.
17. Reeves, W. C., Ruparelia, S. S., & Swanson, K. I. (2003). Long-term follow-up of patients with recurrent respiratory papillomatosis. Archives of Otolaryngology–Head & Neck Surgery, 129(9), 976–982.
18. Rosen, C. A., Bryson, P. C., & Kaplan, S. E. (2019). Surgical and adjuvant therapies for recurrent respiratory papillomatosis. Otolaryngologic Clinics of North America, 52(4), 669–683.
19. Smith, E. M., Ritchie, J. M., & Haugen, T. H. (2010). Human papillomavirus transmission and immune responses in airway disease. Clinical Infectious Diseases, 50(3), 377–384.
20. Stanley, M. (2012). Immunobiology of HPV and host immune response. Gynecologic Oncology, 126(2), 173–178.
21. Sullivan, J. L., Derkay, C. S., & Wiatrak, B. J. (2009). Immune responses and susceptibility in recurrent respiratory papillomatosis. Clinical and Vaccine Immunology, 16(6), 832–838.
22. Tjon Pian Gi, R. E., San Giorgi, M. R., & Pawlita, M. (2013). Therapeutic HPV vaccination in recurrent respiratory papillomatosis: A case series. Vaccine, 31(35), 3660–3664.
23. Wiatrak, B. J. (2003). Overview of recurrent respiratory papillomatosis and HPV-related airway disease. Current Opinion in Otolaryngology & Head and Neck Surgery, 11(6), 433–441.
24. Young, D. L., Moore, M. M., & Halstead, L. A. (2015). T-cell dysfunction in recurrent respiratory papillomatosis. The Laryngoscope, 125(1), E7–E12.
25. Zeitels, S. M., Barbu, A. M., Landau-Zemer, T., & Lopez-Guerra, G. (2011). Local injection of bevacizumab for recurrent respiratory papillomatosis. The Laryngoscope, 121(10), 2231–2237.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5